Mon, March 28, 2011
Sun, March 27, 2011
Fri, March 25, 2011
Thu, March 24, 2011
Wed, March 23, 2011
Tue, March 22, 2011
Mon, March 21, 2011
[ Mon, Mar 21st 2011 ] - Market Wire
30 p.m. ET
Sun, March 20, 2011
Fri, March 18, 2011
Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011

InSite Vision Announces Annual Shareholder Meeting to be Held on June 1, 2011


//health-fitness.news-articles.net/content/2011/ .. areholder-meeting-to-be-held-on-june-1-2011.html
Published in Health and Fitness on Tuesday, March 15th 2011 at 13:40 GMT by Market Wire   Print publication without navigation


ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the companya™s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Wednesday, June 1, 2011, for shareholders of record on April 11, 2011. The Annual Meeting will be held at the companya™s headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Annual Meeting, as well as its annual report, in late-April.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The companya™s product portfolio utilizes InSite Visiona™s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivancea" (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Visiona™s clinical-stage ophthalmic product pipeline includes AzaSite Plusa" (ISV-502) and DexaSitea" (ISV-305) for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].

AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.
BESIVANCEa" is a trademark of Bausch & Lomb Incorporated.


Publication Contributing Sources